| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,660 |
4,426 |
$681K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,093 |
2,019 |
$432K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,190 |
1,148 |
$364K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
9,954 |
3,159 |
$272K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,668 |
2,576 |
$214K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,470 |
1,312 |
$188K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
5,043 |
2,006 |
$131K |
| 71046 |
Radiologic examination, chest; 2 views |
1,578 |
1,532 |
$73K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
1,707 |
791 |
$59K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,103 |
984 |
$47K |
| 80053 |
Comprehensive metabolic panel |
9,191 |
8,630 |
$45K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
190 |
187 |
$43K |
| 84443 |
Thyroid stimulating hormone (TSH) |
4,039 |
3,924 |
$42K |
| 80061 |
Lipid panel |
4,288 |
4,196 |
$39K |
| 36415 |
Collection of venous blood by venipuncture |
17,000 |
14,634 |
$39K |
| 97161 |
|
621 |
619 |
$37K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
2,065 |
959 |
$31K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
497 |
487 |
$29K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
628 |
576 |
$26K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
739 |
725 |
$25K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
241 |
240 |
$25K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,902 |
7,185 |
$25K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,162 |
1,138 |
$22K |
| 71045 |
Radiologic examination, chest; single view |
344 |
338 |
$21K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
240 |
234 |
$18K |
| 97162 |
|
230 |
230 |
$14K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,035 |
2,005 |
$13K |
| 85027 |
|
2,486 |
2,383 |
$10K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,977 |
1,801 |
$8K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
461 |
454 |
$6K |
| 82728 |
|
563 |
546 |
$5K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
810 |
779 |
$4K |
| 83735 |
|
1,474 |
1,273 |
$3K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
18 |
18 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
612 |
573 |
$3K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
25 |
25 |
$2K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
15 |
13 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
572 |
542 |
$2K |
| 81001 |
|
2,951 |
2,788 |
$2K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
113 |
113 |
$2K |
| 82570 |
|
445 |
425 |
$2K |
| 73630 |
|
95 |
91 |
$2K |
| 70450 |
Computed tomography, head or brain; without contrast material |
14 |
14 |
$2K |
| 83540 |
|
368 |
353 |
$2K |
| 85610 |
|
824 |
633 |
$2K |
| 84439 |
|
272 |
252 |
$2K |
| 83550 |
|
207 |
201 |
$1K |
| 86140 |
|
472 |
446 |
$1K |
| 97535 |
Self-care/home management training, each 15 minutes |
54 |
42 |
$984.17 |
| 83690 |
|
785 |
754 |
$862.46 |
| 87081 |
|
316 |
312 |
$859.25 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
45 |
42 |
$853.42 |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
66 |
62 |
$819.17 |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
12 |
12 |
$684.48 |
| 85652 |
|
535 |
505 |
$671.49 |
| 73564 |
|
15 |
14 |
$670.86 |
| 72110 |
|
12 |
12 |
$646.45 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
87 |
85 |
$516.38 |
| 82043 |
|
133 |
130 |
$491.25 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
14 |
14 |
$467.30 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
25 |
25 |
$448.14 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
25 |
24 |
$355.10 |
| 80305 |
|
33 |
30 |
$294.50 |
| 73610 |
|
38 |
38 |
$256.56 |
| 87186 |
|
66 |
64 |
$197.08 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
13 |
13 |
$183.54 |
| 81025 |
|
326 |
317 |
$180.85 |
| 82248 |
|
54 |
52 |
$156.72 |
| 83880 |
|
14 |
14 |
$147.60 |
| 87077 |
|
51 |
49 |
$138.59 |
| 82607 |
|
12 |
12 |
$120.40 |
| 73130 |
|
15 |
14 |
$94.86 |
| 82150 |
|
54 |
54 |
$79.06 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
152 |
76 |
$58.24 |
| 84484 |
|
310 |
239 |
$28.43 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
49 |
47 |
$21.53 |
| 83605 |
|
389 |
359 |
$18.45 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
444 |
411 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
237 |
233 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
433 |
425 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
812 |
763 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
14 |
14 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
13 |
13 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
14 |
13 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
27 |
27 |
$0.00 |
| 87040 |
|
14 |
13 |
$0.00 |